GSK3B and breast carcinoma: In the present work, we observed that GSK3B knockdown and the CP21R7 treatment significantly increased the protein level of the epithelial marker E-cadherin, which is in line with a previous finding that GSK3B inhibition stabilized E-cadherin expression in breast cancer (40).